Insight Molecular Diagnostics (IMDX) Other Operating Expenses (2015 - 2026)

Insight Molecular Diagnostics has reported Other Operating Expenses for 11 years, with the latest figure at -$965000.0 in Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to -$965000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$965000.0 (changed N/A YoY) and the FY2024 annual result came in at -$169000.0, up 86.83% from the prior year.
• Other Operating Expenses fell to -$965000.0 in Q1 2026 per IMDX's latest filing, from -$169000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $5.2 million in Q4 2022 and troughed at -$4.7 million in Q3 2022.
• A 4-year average of -$1.5 million and a median of -$1.3 million in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Operating Expenses sank 252.51% in 2022, then jumped 86.83% in 2024.
• Over 4 years, Other Operating Expenses stood at $5.2 million in 2022, then tumbled by 124.88% to -$1.3 million in 2023, then surged by 86.83% to -$169000.0 in 2024, then plunged by 471.01% to -$965000.0 in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$965000.0, -$169000.0, and -$1.3 million for Q1 2026, Q1 2024, and Q1 2023 respectively.